Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

An NF90/NF110-mediated feedback amplification loop regulates dicer expression and controls ovarian carcinoma progression.

Barbier J, Chen X, Sanchez G, Cai M, Helsmoortel M, Higuchi T, Giraud P, Contreras X, Yuan G, Feng Z, Nait-Saidi R, Deas O, Bluy L, Judde JG, Rouquier S, Ritchie W, Sakamoto S, Xie D, Kiernan R.

Cell Res. 2018 Mar 21. doi: 10.1038/s41422-018-0016-8. [Epub ahead of print]

PMID:
29563539
2.

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.

Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL.

Clin Cancer Res. 2017 Oct 15;23(20):6138-6150. doi: 10.1158/1078-0432.CCR-17-1232. Epub 2017 Jul 27.

PMID:
28751448
3.

Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents.

Gaston J, Cheradame L, Yvonnet V, Deas O, Poupon MF, Judde JG, Cairo S, Goffin V.

Oncotarget. 2016 Nov 22;7(47):77205-77224. doi: 10.18632/oncotarget.12858.

4.

Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management.

Nicolle D, Fabre M, Simon-Coma M, Gorse A, Kappler R, Nonell L, Mallo M, Haidar H, Déas O, Mussini C, Guettier C, Redon MJ, Brugières L, Ghigna MR, Fadel E, Galmiche-Rolland L, Chardot C, Judde JG, Armengol C, Branchereau S, Cairo S.

Hepatology. 2016 Oct;64(4):1121-35. doi: 10.1002/hep.28621. Epub 2016 Jun 16.

PMID:
27115099
5.

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.

Legrier ME, Bièche I, Gaston J, Beurdeley A, Yvonnet V, Déas O, Thuleau A, Château-Joubert S, Servely JL, Vacher S, Lassalle M, Depil S, Tucker GC, Fontaine JJ, Poupon MF, Roman-Roman S, Judde JG, Decaudin D, Cairo S, Marangoni E.

Br J Cancer. 2016 Jan 19;114(2):177-87. doi: 10.1038/bjc.2015.398. Epub 2015 Dec 22.

6.

The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.

Aloia A, Petrova E, Tomiuk S, Bissels U, Déas O, Saini M, Zickgraf FM, Wagner S, Spaich S, Sütterlin M, Schneeweiss A, Reitberger M, Rüberg S, Gerstmayer B, Agorku D, Knöbel S, Terranegra A, Falleni M, Soldati L, Sprick MR, Trumpp A, Judde JG, Bosio A, Cairo S, Hardt O.

Breast Cancer Res. 2015 Nov 25;17(1):146. doi: 10.1186/s13058-015-0652-6.

7.

SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage.

Clifford R, Louis T, Robbe P, Ackroyd S, Burns A, Timbs AT, Wright Colopy G, Dreau H, Sigaux F, Judde JG, Rotger M, Telenti A, Lin YL, Pasero P, Maelfait J, Titsias M, Cohen DR, Henderson SJ, Ross MT, Bentley D, Hillmen P, Pettitt A, Rehwinkel J, Knight SJ, Taylor JC, Crow YJ, Benkirane M, Schuh A.

Blood. 2014 Feb 13;123(7):1021-31. doi: 10.1182/blood-2013-04-490847. Epub 2013 Dec 12.

8.

NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function.

Yatim A, Benne C, Sobhian B, Laurent-Chabalier S, Deas O, Judde JG, Lelievre JD, Levy Y, Benkirane M.

Mol Cell. 2012 Nov 9;48(3):445-58. doi: 10.1016/j.molcel.2012.08.022. Epub 2012 Sep 27.

9.

Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts.

Némati F, Bras-Gonçalves R, Fontaine JJ, de Pinieux G, De Cremoux P, Chapelier A, Daniel C, Laurent-Puig P, Livartowski A, Judde JG, Bordier V, Poupon MF, Decaudin D.

Anticancer Drugs. 2009 Nov;20(10):932-40. doi: 10.1097/CAD.0b013e32833009cc.

PMID:
19741504
10.

STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.

Newman SP, Foster PA, Stengel C, Day JM, Ho YT, Judde JG, Lassalle M, Prevost G, Leese MP, Potter BV, Reed MJ, Purohit A.

Clin Cancer Res. 2008 Jan 15;14(2):597-606. doi: 10.1158/1078-0432.CCR-07-1717.

11.

A new model of patient tumor-derived breast cancer xenografts for preclinical assays.

Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Diéras V, Poupon MF.

Clin Cancer Res. 2007 Jul 1;13(13):3989-98.

12.

Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.

Legrier ME, Oudard S, Judde JG, Guyader C, de Pinieux G, Boyé K, de Cremoux P, Dutrillaux B, Poupon MF.

Br J Cancer. 2007 Jan 29;96(2):269-76. Epub 2007 Jan 9.

13.

Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features.

Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, Saulnier P, Judde JG, Janneau JL, Auger N, Validire P, Dutrillaux B, Praz F, Bellet D, Poupon MF.

Cancer Res. 2007 Jan 1;67(1):398-407.

14.

Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.

Judde JG, Rebucci M, Vogt N, de Cremoux P, Livartowski A, Chapelier A, Tran-Perennou C, Boye K, Defrance R, Poupon MF, Bras-Gonçalves RA.

Int J Cancer. 2007 Apr 1;120(7):1579-90.

15.

Up-regulation of the error-prone DNA polymerase {kappa} promotes pleiotropic genetic alterations and tumorigenesis.

Bavoux C, Leopoldino AM, Bergoglio V, O-Wang J, Ogi T, Bieth A, Judde JG, Pena SD, Poupon MF, Helleday T, Tagawa M, Machado C, Hoffmann JS, Cazaux C.

Cancer Res. 2005 Jan 1;65(1):325-30.

16.

In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.

Decaudin D, de Cremoux P, Sastre X, Judde JG, Nemati F, Tran-Perennou C, Fréneaux P, Livartowski A, Pouillart P, Poupon MF.

Int J Cancer. 2005 Feb 20;113(5):849-56. Review.

17.

Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line.

Abal M, Bras-Goncalves R, Judde JG, Fsihi H, De Cremoux P, Louvard D, Magdelenat H, Robine S, Poupon MF.

Oncogene. 2004 Mar 4;23(9):1737-44.

PMID:
15001986
18.

Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft.

Legrier ME, de Pinieux G, Boyé K, Arvelo F, Judde JG, Fontaine JJ, Bara J, Poupon MF.

Br J Cancer. 2004 Feb 9;90(3):720-7.

19.

Molecular epidemiology of human herpesvirus 8 in africa: both B and A5 K1 genotypes, as well as the M and P genotypes of K14.1/K15 loci, are frequent and widespread.

Lacoste V, Judde JG, Brière J, Tulliez M, Garin B, Kassa-Kelembho E, Morvan J, Couppié P, Clyti E, Forteza Vila J, Rio B, Delmer A, Mauclère P, Gessain A.

Virology. 2000 Dec 5;278(1):60-74.

20.

Virological and molecular characterisation of a new B lymphoid cell line, established from an AIDS patient with primary effusion lymphoma, harbouring both KSHV/HHV8 and EBV viruses.

Lacoste V, Judde JG, Bestett G, Cadranel J, Antoine M, Valensi F, Delabesse E, Macintyre E, Gessain A.

Leuk Lymphoma. 2000 Jul;38(3-4):401-9.

PMID:
10830748
21.

Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases.

Judde JG, Lacoste V, Brière J, Kassa-Kelembho E, Clyti E, Couppié P, Buchrieser C, Tulliez M, Morvan J, Gessain A.

J Natl Cancer Inst. 2000 May 3;92(9):729-36.

PMID:
10793109
22.

Molecular characterization of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 strains from Russia.

Lacoste V, Kadyrova E, Chistiakova I, Gurtsevitch V, Judde JG, Gessain A.

J Gen Virol. 2000 May;81(Pt 5):1217-22.

PMID:
10769063
23.

Sequence variations in EBNA-1 may dictate restriction of tissue distribution of Epstein-Barr virus in normal and tumour cells.

Gutiérrez MI, Raj A, Spangler G, Sharma A, Hussain A, Judde JG, Tsao SW, Yuen PW, Joab I, Magrath IT, Bhatia K.

J Gen Virol. 1997 Jul;78 ( Pt 7):1663-70.

PMID:
9225043
24.

Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas.

Bhatia K, Raj A, Guitierrez MI, Judde JG, Spangler G, Venkatesh H, Magrath IT.

Oncogene. 1996 Jul 4;13(1):177-81.

PMID:
8700544
25.

Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia.

Judde JG, Spangler G, Magrath I, Bhatia K.

Hum Gene Ther. 1996 Mar 20;7(5):647-53.

PMID:
8845390
26.

Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia.

Gutiérrez MI, Judde JG, Magrath IT, Bhatia KG.

Cancer Res. 1996 Mar 1;56(5):969-72.

27.

Metastatic human rhabdomyosarcoma: molecular, cellular and cytogenetic analysis of a novel cellular model.

Kalebic T, Judde JG, Velez-Yanguas M, Knutsen T, Helman LJ.

Invasion Metastasis. 1996;16(2):83-96.

PMID:
9030243
28.

A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma.

Bhatia K, Fan S, Spangler G, Weintraub M, O'Connor PM, Judde JG, Magrath I.

Cancer Res. 1995 Apr 1;55(7):1431-5.

29.
31.
32.

Genotypic and phenotypic evidence of clonal interactions in murine tumor cells.

Itaya T, Judde JG, Hunt B, Frost P.

J Natl Cancer Inst. 1989 May 3;81(9):664-8.

PMID:
2709423
34.

Inhibition of rat natural killer cell function by carcinogenic nickel compounds: preventive action of manganese.

Judde JG, Breillout F, Clemenceau C, Poupon MF, Jasmin C.

J Natl Cancer Inst. 1987 Jun;78(6):1185-90.

PMID:
2438444
35.

Influence of the uremic state on the development of malignancy. An experimental study in the rat.

Soubrane C, Jacobs C, Jacquillat C, Dubois M, Poupon MF, Judde JG, Maral J, Beaufils H, Jaudon MC.

Am J Nephrol. 1986;6(5):363-8.

PMID:
3826134
36.

In vitro electron microprobe of carcinogenic nickel compound interaction with tumor cells.

Berry JP, Poupon MF, Judde JC, Galle P.

Ann Clin Lab Sci. 1985 Mar-Apr;15(2):109-20.

PMID:
3994286
37.

Electron microprobe in vitro study of interaction of carcinogenic nickel compounds with tumour cells.

Berry JP, Galle P, Poupon MF, Pot-Deprun J, Chouroulinkov I, Judde JG, Dewally D.

IARC Sci Publ. 1984;(53):153-64.

PMID:
6099827
38.

Supplemental Content

Support Center